{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:11Z","timestamp":1791260171683,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40268-018-0251-y","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:48:14Z","timestamp":1539132494000},"page":"317-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Isavuconazole Kinetic Exploration for Clinical Practice"],"prefix":"10.1007","volume":"18","author":[{"given":"L\u00e9a","family":"Darnaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Lamoureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cendrine","family":"Godet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Pontier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Debard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Venisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Concordet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Gandia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"issue":"11","key":"251_CR1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/17425255.2017.1391213","volume":"13","author":"JR Amsden","year":"2017","unstructured":"Amsden JR, Gubbins PO. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy. Expert Opin Drug Metab Toxicol. 2017;13(11):1135\u201346.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"10","key":"251_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpdd.285","volume":"6","author":"R Townsend","year":"2017","unstructured":"Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interaction of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017;6(10):44\u201353.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"3","key":"251_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/ajt.13059","volume":"15","author":"N Pallet","year":"2015","unstructured":"Pallet N, Jannot AS, El Bahri M, et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Am J Transplant. 2015;15(3):800\u20135.","journal-title":"Am J Transplant"},{"issue":"12","key":"251_CR4","doi-asserted-by":"publisher","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","volume":"61","author":"A Desai","year":"2017","unstructured":"Desai A, Kovanda LL, Hope W, et al. Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi. Antimicrob Agents Chemother. 2017;61(12):e01034-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"251_CR5","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/jac\/dkw098","volume":"71","author":"LL Kovanda","year":"2016","unstructured":"Kovanda LL, Petraitiene R, Petraitis V, et al. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. J Antimicrob Chemother. 2016;71(7):1885\u201391.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"251_CR6","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1128\/AAC.02665-15","volume":"60","author":"V Petraitis","year":"2016","unstructured":"Petraitis V, Petraitiene R, Moradi PW, et al. Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2016;60(5):2718\u201326.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"251_CR7","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1128\/AAC.01355-13","volume":"57","author":"AJ Lepak","year":"2013","unstructured":"Lepak AJ, Marchillo K, Vanhecker J, Andes DR. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57(12):6284\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"251_CR8","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1128\/AAC.04907-14","volume":"59","author":"S Seyedmousavi","year":"2015","unstructured":"Seyedmousavi S, Bruggemann RJ, Meis JF, et al. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother. 2015;59:2855\u201366.","journal-title":"Antimicrob Agents Chemother"},{"key":"251_CR9","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1128\/AAC.02819-15","volume":"60","author":"A Desai","year":"2016","unstructured":"Desai A, Kovanda LL, Kowalski D, et al. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60:5483\u201391.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10020","key":"251_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomized-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139.","journal-title":"Lancet"},{"key":"251_CR11","doi-asserted-by":"publisher","unstructured":"Andes D, Kovanda L, Desai A, et al. Isavuconazole concentration in real-world practice: consistency with results from clinical trials. Antimicrob Agents Chemother. 2018;62(7), pii: e00585\u201318. https:\/\/doi.org\/10.1128\/AAC.00585-18","DOI":"10.1128\/AAC.00585-18"},{"issue":"9","key":"251_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2217\/pgs.13.80","volume":"14","author":"VM Gijsen","year":"2013","unstructured":"Gijsen VM, Schaik RH, Elens L, et al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics. 2013;14(9):1027\u201336.","journal-title":"Pharmacogenomics."},{"issue":"7","key":"251_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/FPC.0b013e328351d47f","volume":"22","author":"J Lamba","year":"2012","unstructured":"Lamba J, Hebert JM, Schuetz EG, et al. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012;22(7):555\u20138.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"251_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/pgs.12.187","volume":"14","author":"L Elens","year":"2013","unstructured":"Elens L, van Gelder T, Hesselink DA, et al. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013;14(1):47\u201362.","journal-title":"Pharmacogenomics."},{"issue":"3","key":"251_CR15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0022-3565(24)29199-0","volume":"299","author":"D Dai","year":"2001","unstructured":"Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299(3):825\u201331.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-018-0251-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0251-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0251-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:13:56Z","timestamp":1775243636000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-018-0251-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0251-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"10 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors received no funding for this project: the data have been generated as part of routine work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have no conflicts of interest that are directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}